Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Assessment of atorvastatin efficacy on the progression of aortic dilatation and valvular degeneration in patients with bicuspid aortic valve (BICATOR)
2015-001808-57Phase 3Active
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of atorvastatin in bicuspid aortic valve (BAV), ascending thoracic aortic aneurysm (ATAA) and aortic valve disease (AVD), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Progression of aortic dilatation of the ascending aorta. Started Oct 2015; status: active.
02
Drugs
atorvastatin
03
Conditions
bicuspid aortic valve (BAV)ascending thoracic aortic aneurysm (ATAA)aortic valve disease (AVD)
Beyond the preview
Go deeper on 2015-001808-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001808-57.